Servier to Acquire Day One Biopharmaceuticals for $21.50/Share, Valuing Company at $2.5 Billion

summarizeSummary

Day One Biopharmaceuticals has agreed to be acquired by Servier Pharmaceuticals LLC for $21.50 per share in cash, valuing the company at approximately $2.5 billion, representing a significant premium for shareholders.

check_boxKey Events

• Definitive Merger Agreement

  Day One Biopharmaceuticals, Inc. has entered into an Agreement and Plan of Merger with Servier Pharmaceuticals LLC and Servier Detroit Inc. (Merger Sub).

• Acquisition Price and Valuation

  Servier will acquire all outstanding shares of Day One common stock for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. This is a significant premium over the current stock price and the 52-week high.

• Board Recommendation

  Day One's Board of Directors has unanimously approved the merger and recommends that shareholders accept the tender offer and tender their shares.

• Strategic Rationale

  The acquisition aims to strengthen Servier's position in rare oncology and expand its pipeline, leveraging Day One's scientific expertise and lead program in pediatric low-grade glioma (OJEMDA).

auto_awesomeAnalysis

Day One Biopharmaceuticals has entered into a definitive agreement to be acquired by Servier Pharmaceuticals LLC for $21.50 per share in cash. This represents a substantial premium of approximately 68.6% over the current stock price and significantly above the company's 52-week high of $13.20, offering a strong exit for shareholders. The total equity value of approximately $2.5 billion nearly doubles the company's current market capitalization. This acquisition follows recent positive developments, including strong financial results and a positive EMA opinion for its lead drug OJEMDA, which likely enhanced its appeal as an acquisition target. The Board's unanimous recommendation to tender shares indicates strong internal support for the deal. The transaction is subject to customary closing conditions, including majority tender and U.S. antitrust clearance, and is expected to close in Q2 2026. A termination fee of $87.7 million is in place, providing a significant deterrent to competing offers.